| Description | Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit/hyperactivity disorder (ADHD). |
| In vitro | Sofiniclin is more potent than ABT-089 at both receptor subtypes, with Ki values of 1.3 nM for 125I-epibatidine binding and of 1.9 nM for 125I-α-conotoxinMII binding [1]. |
| In vivo | Compared to vehicle monkey, Sofiniclin (0.001 to 0.10 mg/kg, p.o.) produces significant reductions in LIDs [1]. Sofiniclin (0.1 mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage [2]. |
| Synonyms | ABT 894 |
| molecular weight | 244.12 |
| Molecular formula | C10H11Cl2N3 |
| CAS | 799279-80-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Zhang D, et al. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29(4):508-17. 2. Zhang D, ET AL. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30(14):1901-11. |